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Abstract: Metastatic melanoma is an aggressive skin cancer with a relatively low survival rate.
Immune-based therapies have shown promise in the treatment of melanoma, but overall complete
response rates are still low. Previous studies have demonstrated the potential of plasmid IL-12
(pIL-12) delivered by gene electrotransfer (GET) to be an effective immunotherapy for melanoma.
However, events occurring in the tumor microenvironment following delivery have not been
delineated. Therefore, utilizing a B16F10 mouse melanoma model, we evaluated changes in the
tumor microenvironment following delivery of pIL-12 using different GET parameters or injection of
plasmid alone. The results revealed a unique immune cell composition after intratumoral injection of
pIL-12 GET. The number of immune memory cells was markedly increased in pIL-12 GET melanoma
groups compared to control group. This was validated using flow cytometry to analyze peripheral
blood mononuclear cells as well as delineating immune cell content using immunohistochemistry.
Significant differences in multiple cell types were observed, including CD8+ T cells, regulatory
T cells and myeloid cells, which were induced to mount a CD8+ PD1− T cells immune response.
Taken together, these findings suggest a basic understanding of the sequence of immune activity
following pIL-12 GET and also illuminates that adjuvant immunotherapy can have a positive influence
on the host immune response to cancer.
Keywords: immunotherapy; gene therapy; melanoma; IL-12; electrotransfer

1. Introduction
Effective treatment options for melanoma are significantly limited, especially for metastatic
melanoma and recurrent disease. Surgery and radiotherapy mainly provide palliation, and chemotherapy
has failed to show any consistent survival benefit [1,2]. To effectively treat metastatic disease with
immunotherapy, it is important to induce a systemic immune response and/or induce memory T cells
that can specifically target the primary tumor or recurrences [3]. Interleukin 12 (IL-12) is an ideal
candidate for tumor immunotherapy, due to its ability to activate both innate (NK cells) and adaptive
(cytotoxic T lymphocytes) responses and to potently stimulate the production of IFN-γ leading to a
potentially effective anticancer defense [4,5]. However, despite encouraging results in animal models,
very modest antitumor effects of IL-12 were achieved in early clinical trials, often accompanied by
unacceptable levels of adverse events, which markedly dampened hopes of the successful use of this
cytokine in cancer patients [6,7].
An alternative strategy to enhance an antitumor immune response is to deliver the cytokine
gene directly into tumors. Previous studies have found that IL-12 plasmid delivered by in vivo
electroporation (pIL-12 GET) generated successful treatment of established subcutaneous melanoma
tumors with minimal to no toxicity in both preclinical and clinical studies [3,8–10]. Local expression
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of IL-12 led to recruitment of immune cells infiltrating the tumor microenvironment, which have
been directly associated with favorable clinical outcomes, including disease-free survival, and overall
survival in various solid tumors, including melanoma [11,12].
Tumor-infiltrating lymphocytes (TILs) are a heterogeneous group comprised of not only effector T
cells, but also of tolerogenic or T regulatory (Treg) cells, functionally exhausted T cells, myeloid-derived
suppressor cells (MDSCs), and other immune cell types. Thus, mapping the immune compartment of
B16F10 melanoma tumors could allow a better understanding of the immunologic circuits active after
pIL-12 GET in this malignancy.
The present study was designed to evaluate changes in the makeup of peripheral blood
mononuclear cells (PBMCs) and immune cells within the tumor microenvironment following pIL-12
GET. Peripheral blood analysis was included to provide insights about the immune response induced
following pIL-12 GET, furthermore, peripheral blood analyses may provide a systemic view of the
immune response and can be repeated at several time points. Local antitumor immunity was analyzed
by the enumeration of tumor-infiltrating lymphocytes. The results demonstrated that pIL-12 GET
results in decreased levels of PD1 expression on CD4+ and CD8+ T cells, percentage of Treg cells in
the tumor and increased infiltration of CD8+ PD1− T cells leading to better control of tumor growth,
strongly suggesting that therapy with pIL-12 GET has the potential to improve outcomes.
2. Results
2.1. Tumor Regression and Protection Against Rechallenge by pIL-12 GET
Motivated by the synergy observed between expression kinetics and expression levels of
IL-12 related to the applied electric pulse parameters in our previous study [10], we explored
two different GET treatments, pIL-12 EP1 and pIL-12 EP2. An intratumoral injection of pIL-12
followed by electroporation pulsing sequence 1 (EP1—six 1300 V/cm, 100 µs pulses with an array
of 6 penetrating electrodes) or electroporation pulsing sequence 2 (EP2—ten 600 V/cm, 5 ms pulses
with a non-penetrating caliper electrodes) was performed 3 times on days 0, 4 and 7 (Figure 1A).
pIL-12 GET induced a robust tumor regression (Figure 1B) compared with no treatment (TX), pIL-12
injection only, EP1 no IL-12 and EP2 no IL-12 groups. A significant difference in reduction of tumor
volume was observed with pIL-12 GET (p < 0.001). Durable cures of around 80% in pIL-12 EP1 and
65% in pIL-12 EP2 of mice bearing B16F10 melanoma tumors (Figure 1C), while pIL-12 injection only
elicited weaker therapeutic response (Figure 1B, C). 50–60 days after cessation of therapy, tumor free
mice were rechallenged with an injection of 5 × 105 B16F10 cells into the opposite flank. Around
50% of the pIL-12 GET mice remained tumor free after the rechallenge, suggesting the induction of
effective immunological memory (Figure 1D). Importantly, despite high rates of response, pIL-12 GET
therapy was associated with minimal systemic toxicity, as mice did not show weight loss (Figure S1).
In previous experiments, we have not observed tumor recurrence in mice that were tumor-free at
120 days, even after regular observation for more than a half year, and therefore in the present study,
mice that were tumor-free at 120 days were deemed to have mounted a long-term response and were
euthanized [10].

Cancers 2018, 10, 498
Cancers 2018, 10, x

3 of 19
3 of 19

Figure
1. 1.Antitumor
B16F10tumor-bearing
tumor-bearing
mice
treated
with
IL-12
plasmid
delivered
Figure
Antitumorefficacy
efficacy in
in B16F10
mice
treated
with
IL-12
plasmid
delivered
by
by ininvivo
vivo electroporation
electroporation(pIL-12
(pIL-12
GET)
and
protective
immunity
against
tumor
rechallenge.
GET) and protective immunity against tumor rechallenge. (A)
(A)Experimental
Experimental
scheme.
day-7,
C57BL/6
inoculated
with B16F10
106s.c
/50
/50×μL,
scheme.
OnOn
day-7,
C57BL/6
micemice
were were
inoculated
with B16F10
cells (1cells
× 106(1
µL,ins.c
inleft
theflank.).
left flank.).
Tumor-bearing
C57BL/6
mice
were with
treated
withGET
pIL-12
GET 0,
on4days
0, 4
the
Tumor-bearing
C57BL/6
mice were
treated
pIL-12
on days
and 7.
andSpleen
7. Spleen
and tumor
tissues
collected
on9.day
On60,day
60,term
longsurviving
term surviving
tumor-free
and tumor
tissues
were were
collected
on day
On 9.
day
long
tumor-free
mice
5 /50
5/50
μL).
TheThe
end
point
time
of of
were
rechallenged
byby
injection
of of
B16F10
cells
at at
half
1010
mice
were
rechallenged
injection
B16F10
cells
halfdose
dose(5(5× ×
µL).
end
point
time
experiment
was
Tumor
volume
monitored
recorded
every
2–3 days
the
experiment
was
dayday
120.120.
(B)(B)
Tumor
volume
waswas
monitored
andand
recorded
every
2–3 days
untiluntil
the tumor
tumorreached
volumethe
reached
the end
point.
(C) Overall
was determined
throughout
a 50-day
time
volume
end point.
(C)
Overall
survivalsurvival
was determined
throughout
a 50-day
time course.
5) from
5
course.
(D)
Percentage
of
tumor
incidence
after
rechallenge.
(E,
F)
On
day
9,
splenocytes
(1
×
10
(D) Percentage of tumor incidence after rechallenge. (E, F) On day 9, splenocytes (1 × 10 ) from B16F10
B16F10 tumor-bearing
were incubated
withtarget
B16F10cells
target
48 h in plates
96-wellinplates
in
tumor-bearing
mice weremice
incubated
with B16F10
for cells
48 h for
in 96-well
triplicate
triplicate
(200
at ratio
of 20:1. B
Granzyme
B spots
in enzyme-linked
immunospot
(200
µL/well)
at μL/well)
ratio of 20:1.
Granzyme
spots counted
in counted
enzyme-linked
immunospot
(ELISPOT).
6) from B16F10 tumor-bearing mice were incubated with
(ELISPOT).
(G, H)
(1 × 10tumor-bearing
(G,H)
Splenocytes
(1 ×Splenocytes
106 ) from B16F10
mice were incubated with carboxyfluorscein
carboxyfluorscein
succinimidyl
ester (CFSE)
stained-B16F10
target tube
cells in
in u-bottom
in triplicate
succinimidyl
ester (CFSE)
stained-B16F10
target
cells in u-bottom
triplicate tube
at ratio
of 20:1 for
at
ratio
of
20:1
for
4
h.
The
cytotoxic
activity
was
measured
by
flow
cytometric
analysis
+
+ cells (killed
4 h. The cytotoxic activity was measured by flow cytometric analysis comparing CFSE PIcomparing
CFSE+PI+cells (killed targets) with CFSE+PI-cells killing. Pooled data from two independent
targets) with CFSE+ PI- cells killing. Pooled data from two independent experiments are shown. Each
experiments are shown. Each value represents the mean +/− SEM of the group (animals in each group,
value represents the mean +/− SEM of the group (animals in each group, n = 8–13). One-way ANOVA,
n = 8–13). One-way ANOVA, p * < 0.05, p ** < 0.01, p ***< 0.001.
p * < 0.05, p ** < 0.01, p ***< 0.001.

better understand the response, anti-tumor cell activity present following three pIL-12 GET
ToTo
better
understand the response, anti-tumor cell activity present following three pIL-12 GET
treatments was analyzed. Spleens were collected on Day 9 and splenocytes isolated. Splenocytes were
treatments was analyzed. Spleens were collected on Day 9 and splenocytes isolated. Splenocytes were
co-cultured with B16F10 melanoma cells for 2 days and then evaluated by ELISPOT. Since the tumor
co-cultured with B16F10 melanoma cells for 2 days and then evaluated by ELISPOT. Since the tumor
volume and percentage of survival were similar among no TX, EP1 and EP2 group, the next analysis
volume and percentage of survival were similar among no TX, EP1 and EP2 group, the next analysis
was performed on no TX, pIL-12, pIL-12 EP1 and pIL-12 EP2 groups. Splenocytes isolated from mice
was performed on no TX, pIL-12, pIL-12 EP1 and pIL-12 EP2 groups. Splenocytes isolated from mice
treated with pIL-12 GET released more Granzyme B compared to no TX and pIL-12 injection only
treated
with
pIL-12
GETSimilarly,
releasedinmore
Granzyme
compared
no TX andfrom
pIL-12
injection
only
groups
(Figure
1F,G).
a flow
cytometryBkilling
assay,tosplenocytes
pIL-12
EP1 and
groups
(Figure
1F,G).achieved
Similarly,higher
in a flow
cytometry
killing
splenocytes
EP1 and
pIL-12
EP2 groups
cytotoxic
activity
to killassay,
B16F10
melanomafrom
targetpIL-12
cells (Figure
pIL-12
EP2
groups
achieved
higher
cytotoxic
activity
to
kill
B16F10
melanoma
target
cells
(Figure
1H,I).
1H,I). These results suggest that the enhanced antitumor efficacy of pIL-12 GET treatment was
These
results
suggest
that
the
enhanced
antitumor
efficacy
of
pIL-12
GET
treatment
was
associated
with
associated with the reduced-tumor volume and prolonged-survival. Furthermore, pIL-12 GET
theinduced
reduced-tumor
volume
andresponse
prolonged-survival.
pIL-12 GET induced an immune
an immune
memory
that protectedFurthermore,
against rechallenge.
memory response that protected against rechallenge.
2.2. pIL-12 GET Therapy Impacts Tumor Immune Infiltration

Cancers 2018, 10, 498

4 of 19

2.2. pIL-12 GET Therapy Impacts Tumor Immune Infiltration
Cancers 2018, 10, x

4 of 19

The majority of immunotherapeutic approaches are based on the ability of the adaptive
majority
of immunotherapeutic
approaches
are based response.
on the ability
the adaptivethe
immune
immuneThe
system
to infiltrate
tumors and elicit
an anti-tumor
Toof
understand
cellular
system
to
infiltrate
tumors
and
elicit
an
anti-tumor
response.
To
understand
the
cellular
mechanism
mechanism underlying the observed therapeutic effect of pIL-12 GET therapy, we further analyzed the
underlying
the observed
therapeutic
effect model,
of pIL-12
GET therapy,
wean
further
analyzed the immune
immune
response
in the B16F10
melanoma
which
represents
immunosuppressive
tumor
response in the B16F10 melanoma model, which represents an immunosuppressive tumor
microenvironment with low expression of MHC class I (MHC-I) molecules and high PDL1 expression
microenvironment with low expression of MHC class I (MHC-I) molecules and high PDL1 expression
(Figure S2). The loss of MHC-I expression on tumor cells is an immune escape strategy aimed to avoid
(Figure S2). The loss of MHC-I expression on tumor cells is an immune escape strategy aimed to avoid
T-cell recognition which is commonly found in malignant cells. In addition, one of the protective
T-cell recognition which is commonly found in malignant cells. In addition, one of the protective
mechanisms utilized by melanoma cells is through overexpression of PD-L1; as a result, it circumvents
mechanisms utilized by melanoma cells is through overexpression of PD-L1; as a result, it
the generation of an immune response to the tumor. We observed that most of the immune cells formed
circumvents the generation of an immune response to the tumor. We observed that most of the
aggregates
outside theand
tumor
mass
although
they were
close proximity
immune and
cells resided
formed aggregates
resided
outside
the tumor
mass in
although
they weretointumors,
close
andproximity
blood vessels.
However,
after
pIL-12
GET,
there
was
an
increase
of
lymphocytic
infiltrate
into
to tumors, and blood vessels. However, after pIL-12 GET, there was an increase ofthe
tumor
mass
(Figure
2). into the tumor mass (Figure 2).
lymphocytic infiltrate

Figure 2. Cont.

Cancers 2018, 10, 498
Cancers 2018, 10, x

5 of 19
5 of 19

Figure
2. pIL-12
GET
location.Tumors
Tumorswere
werecollected
collectedatat
day
9 for
Figure
2. pIL-12
GETimpacts
impactstumor
tumorimmune
immune infiltration
infiltration location.
day
9 for
histological
analysis.
were stained
stainedwith
withanti-CD3
anti-CD3(green,
(green,
Opal
520).
histological
analysis.Paraffin
Paraffinsections
sectionsof
oftumor
tumor tissue were
Opal
520).
Opal
570570
(red
color)
was
of anti-CD3.
anti-CD3.Results
Resultsare
are
given
Opal
(red
color)
wasused
usedtotoconfirm
confirmthe
thenon-specific
non-specific staining
staining of
given
as as
+
+
cellsfrom
fromthe
thedifferent
differentgroups.
groups. Three
Three mice
location
CD3cells
thethe
location
of of
CD3
mice per
per group.
group.Visualized
Visualizedbybyoptical
optical
microscopy
Red:Opal
Opal 570;
570; Green:
Green: Opal
(DAPI).
microscopy
(×(×200).
200). Red:
Opal 520;
520;Blue:
Blue:4',6-diamidino-2-phenylindole
4’,6-diamidino-2-phenylindole
(DAPI).

The
distribution
GET treatment
treatmentresulting
resultingininananexpansion
expansion
The
distributionofofTILs
TILschanged
changedfollowing
following pIL-12
pIL-12 GET
of of
+ T+ cells
+ cells
+T
CD3
T cells
infiltratingininthe
thetumor
tumorenvironment,
environment,which
which involved
involved CD4++and
(Figure
3A)
CD3
infiltrating
andCD8
CD8
T cells
(Figure
3A)
compared
with
TX,EP1,
EP1,EP2
EP2and
andpIL-12
pIL-12injection
injection only
only groups.
groups. An
cells
is is
compared
with
nono
TX,
Anabundance
abundanceofofthese
these
cells
typically
associated
withfavorable
favorableresponse
response to
to immunotherapy.
immunotherapy. Quantification
typically
associated
with
Quantificationofoftumor-infiltrating
tumor-infiltrating
lymphocytes
revealed
more
lymphocytes
infiltrated
in
the
tumor
lymphocytes revealed more lymphocytes infiltrated in the tumor microenvironment
microenvironmentwith
witheffective
effective
therapies
(Figure
3B–E).There
Therewas
wasaanoticeable
noticeable difference
difference comparing
to to
nono
TX,TX,
therapies
(Figure
3B–E).
comparingpIL-12
pIL-12GET
GETgroups
groups
+, CD4+ and CD8+ T cells. In
EP1,
EP2
and
pIL-12
injection
only
groups
(p
<
0.001)
in
density
of
CD3
+
+
+
EP1, EP2 and pIL-12 injection only groups (p < 0.001) in density of CD3 , CD4 and CD8 T cells.
comparing the 6 groups, we observed no significant difference in the ratios of CD4++/CD8+ T+ cells
In comparing
the 6 groups, we observed no significant difference in the ratios of CD4 /CD8 T cells
among groups, but the ratio was reversed Further characterization of the microenvironment
among groups, but the ratio was reversed Further characterization of the microenvironment evaluated
evaluated the presence of T regulatory cells (Treg) and the presence of T cells positive for PD1. There
the presence of T regulatory cells (Treg) and the presence of T cells positive
for PD1. There was a
was a significant decrease in percentage of PD1 positive cells, both CD4+ and CD8+ cells, and Treg
significant decrease in percentage of PD1 positive cells, both CD4+ and CD8+ cells, and Treg cells
cells following treatment with pIL-12 GET with EP1 (Figure 4). Consistent with IHC results,
following treatment with pIL-12 GET with EP1 (Figure 4). Consistent with IHC results, evaluation
evaluation of cell populations by flow cytometry revealed a reduction of Treg cells
in CD4+ T cells
+ T cells and PD1+ in
of cell
populations
by
flow
cytometry
revealed
a
reduction
of
Treg
cells
in
CD4
and PD1+ in CD4+ or CD8+ T cells after pIL-12 GET or EP1 and EP2 treatment (Figure S3).
CD4+ or CD8+ T cells after pIL-12 GET or EP1 and EP2 treatment (Figure S3).

Cancers 2018, 10, 498

6 of 19

Cancers 2018, 10, x

6 of 19

Figure 3. Cont.

Cancers 2018, 10, 498
Cancers 2018, 10, x

7 of 19
7 of 19

Figure
3. 3.pIL-12
infiltrating lymphocyte
lymphocyte(TILs)
(TILs)
density
in the
Tumor
Figure
pIL-12GET
GET enhances
enhances tumor
tumor infiltrating
density
in the
Tumor
Microenvironment.
(A)(A)
Tumors
forhistological
histologicalanalysis.
analysis.
Paraffin
sections
Microenvironment.
Tumorswere
werecollected
collected on
on day 99 for
Paraffin
sections
of of
tumor
tissue
were
stained
withanti-CD3,
anti-CD3,anti-CD4
anti-CD4 and
and anti-CD8.
byby
optical
microscope
tumor
tissue
were
stained
with
anti-CD8.Visualized
Visualized
optical
microscope
(×200).
(B–D)
Representativeimmunohistochemical
immunohistochemical analysis
GET.
The
density
of TILs
waswas
(×200).
(B–D)
Representative
analysisofofpIL-12
pIL-12
GET.
The
density
of TILs
quantified
in 10–20
random
fields(number
(numberof
oftotal
total cells
cells >>200).
bars
indicate
mean
values.
quantified
in 10–20
random
fields
200).Horizontal
Horizontal
bars
indicate
mean
values.
+ +
(C, (C,
D) IHC
presented
representativeofoftwo
twoindependent
independent experiments.
The The
datadata
presented
areare
representative
experiments.(B)
(B)CD3
CD3density.
density.
D) IHC
+ and CD8+. (E) The percentage of CD4+ and CD8+ cells
represented as the mean density of CD4
datadata
represented
as the mean density of CD4+ and
CD8+ . (E) The percentage of CD4+ and CD8+ cells
+ cells. Each value represents the mean +/− SEM of the group. Pooled data from two
among total CD3
+
among total CD3 cells. Each value represents the mean +/− SEM of the group. Pooled data from two
independent experiments are shown. One-way ANOVA, p * < 0.05, p ***< 0.001.
independent experiments are shown. One-way ANOVA, p * < 0.05, p ***< 0.001.

A Dynamic
Immune
ResponseOccurs
OccursininMice
Mice with
with B16F10
GET
2.3. 2.3.
A Dynamic
Immune
Response
B16F10Tumors
Tumorsafter
afterpIL-12
pIL-12
GET
We next decided to perform a study of the immune kinetics over the full course of treatment. In
We next decided to perform a study of the immune kinetics over the full course of treatment.
B16F10 melanoma tumor-bearing mice, pIL-12 EP1 and pIL-12 EP2 treatment partially controlled
In B16F10 melanoma tumor-bearing mice, pIL-12 EP1 and pIL-12 EP2 treatment partially controlled
disease progression and around 65–80% of mice achieved long-term disease-free survival (Figure 1C).
disease
progression and around 65–80% of mice achieved long-term disease-free survival (Figure 1C).
The near equal efficacy in tumor control with pIL12 EP1 as compared to pIL12 EP2. Thus, we pooled
The pIL-12
near equal
efficacy
in tumor
control
with
pIL12 EP1
compared
to pIL12tumor
EP2. Thus,
we pooled
EP1 and
pIL-12
EP2 groups.
Two
outcomes
wereasobserved,
long-term
free survival.
pIL-12
EP1 and
pIL-12response,
EP2 groups.
Two
outcomes
long-term
tumor
free survival.
(termed:
complete
CR), or
mice
that had were
early observed,
tumor control
followed
by progressive
(termed:
complete
response,
or mice
had early
control
followed
by progressive
outgrowth
(termed:
partial CR),
response,
PR). that
To allow
for thetumor
dynamic
assessment
of the
immune
outgrowth
partial
PR).
To allow
the dynamic
assessment
of the immune
response(termed:
and to explore
theresponse,
mechanism
underlying
thefor
pIL-12
GET, peripheral
blood mononuclear
cells (PBMC)
B16F10
melanoma tumor-bearing
micepIL-12
were evaluated
at pre-treatment,
9, 17, 27,
response
and to from
explore
the mechanism
underlying the
GET, peripheral
blood mononuclear
47, 60 days
treatment
with flow
cytometry. mice were evaluated at pre-treatment, 9, 17, 27,
cells37,
(PBMC)
frompost
B16F10
melanoma
tumor-bearing

37, 47, 60 days post treatment with flow cytometry.

Cancers 2018, 10, 498

8 of 19

Cancers 2018, 10, x

8 of 19

Figure 4. Cont.

Cancers 2018, 10, 498

9 of 19

Cancers 2018, 10, x

9 of 19

Figure 4. Cont.

Cancers 2018, 10, 498
Cancers 2018, 10, x

10 of 19
10 of 19

Figure
4. Changes
in the
Tumor
Microenvironment following
following pmIL-12
GET.
Tumors
were
collected
Figure
4. Changes
in the
Tumor
Microenvironment
pmIL-12
GET.
Tumors
were
collected
for histological
analysis.
(A)Paraffin
Paraffinsections
sections of
were
stained
withwith
anti-CD4,
at dayat9day
for 9histological
analysis.
(A)
of tumor
tumortissue
tissue
were
stained
anti-CD4,
anti-Foxp3
and anti-PD1.
Paraffin
sectionsof
oftumor
tumor tissue
with
anti-CD4,
anti-Foxp3
anti-Foxp3
and anti-PD1.
(B)(B)
Paraffin
sections
tissuewere
werestained
stained
with
anti-CD4,
anti-Foxp3
and
anti-PD1.
Visualized
by
optical
microscope
(×200).
(C,
D)
IHC
data
represented
as
the
and anti-PD1. Visualized by optical microscope (×200). (C, D) IHC data represented as mean
the mean
percentage of Treg cells in CD4+ and exhausted CD4+ PD1+ cells in CD4+ cells in four different groups.
percentage of Treg cells in CD4+ and exhausted CD4+ PD1+ cells in CD4+ cells in four different groups.
(E, F) The ratio of CD8+ T cells to CD4+Foxp3+ Treg cells. The data presented are representative of two
(E, F) The ratio of CD8+ T cells to CD4+ Foxp3+ Treg cells. The data presented are representative of two
independent experiments. Each value represents the mean +/− SEM of the group. The percentage of
independent experiments. Each value represents the mean +/− SEM of the group. The percentage of
TIL was quantified in 10–20 random fields (number of total cells > 200). Horizontal bars indicate mean
TIL was
quantified
inANOVA,
10–20 random
fields
of total
values.
One-way
p * < 0.05,
p **(number
< 0.01, p ***<
0.001.cells > 200). Horizontal bars indicate mean
values. One-way ANOVA, p * < 0.05, p ** < 0.01, p ***< 0.001.

In mice, CD4+ and CD8+ T cells can be further categorized into memory and naïve phenotypes

+
+
In
mice,
cells can be
further
categorized
into memory
and naïve
−CD62L− population
based
onCD4
CD44 and
and CD8
CD62LTexpression
with
the CD44
considered
naïvephenotypes
T cells
−
−
+
+
+
based(Ton
CD62L
expression
with the
CD44
CD62L
population
considered
naïve T cells
N),CD44
CD44 and
CD62L
population
considered
central
memory
T cells
(TCM), CD44
CD62L− population
+ population
+ CD62Leffector
− population
−CD62LT
− (T
effector
memory Tconsidered
cells (TEM) central
and CD44
E) population
considered
T
(TN ), considered
CD44+ CD62L
memory
cells
(TCM ), CD44
+ and CD8+ cells differ in
−
−
cells.
It
is
known
that
CD4
their
distribution
of
these
subsets
in
central
considered effector memory T cells (TEM ) and CD44 CD62L (TE ) population considered effector
+ cellsand
immune
organs,that
peripheral
immune
peripheral
circulation
To better
T cells.
It is known
CD4+ and
CD8organs
differ
in theirblood
distribution
of [2,9,13–15].
these subsets
in central
+
understand
the
mechanism
behind
the
pIL-12
GET
induced
tumor
regression,
we
evaluated
immune organs, peripheral immune organs and peripheral blood circulation [2,9,13–15]. CD4
To better
and CD8+ T cell memory phenotype status in peripheral blood at different time points. TCM CD4+ and+
understand
the mechanism behind the pIL-12 GET induced tumor regression, we evaluated CD4 and
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and then decreased slower than in CR mice. It was also observed that the number of cells were directly
related to the size of the tumor (Figures 1B, 5 and 6).
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3. Discussion
3. Discussion
A major hurdle for cancer immunotherapy is that the majority of tumor cells and their associated
A major hurdle for cancer immunotherapy is that the majority of tumor cells and their associated
antigens are located in an immunosuppressive tumor environment. Despite the fact that large
antigens are located in an immunosuppressive tumor environment. Despite the fact that large
populations of tumor-reactive T cells can be raised in patients, T cells cannot fully realize their
populations of tumor-reactive T cells can be raised in patients, T cells cannot fully realize their
tumoricidal potential within the tumor. Therefore, an abundance of inactivated T cells do not
tumoricidal potential within the tumor. Therefore, an abundance of inactivated T cells do not readily
readily translate to tumor destruction [20]. An important component would be the conversion of the
translate to tumor destruction [20]. An important component would be the conversion of the tumor
tumor microenvironment into an immunosupportive environment, thereby enabling the employment
microenvironment into an immunosupportive environment, thereby enabling the employment of
of tumor antigens in an immunostimulatory context. Immunogenic conversion of the tumor
tumor antigens in an immunostimulatory context. Immunogenic conversion of the tumor
microenvironment can be achieved by intratumoral administration of appropriate immunostimulatory
microenvironment can be achieved by intratumoral administration of appropriate
compounds such as IL-12. However, systemic administration of recombinant IL-12 in clinical trials for
immunostimulatory compounds such as IL-12. However, systemic administration of recombinant ILvarious cancers resulted in some objective responses but also resulted in severe adverse effects [21].
12 in clinical trials for various cancers resulted in some objective responses but also resulted in severe
The goal of pIL-12 GET is to initiate or reinitiate a self-sustaining cycle of anti-tumor immunity,
adverse effects [21]. The goal of pIL-12 GET is to initiate or reinitiate a self-sustaining cycle of antienabling it to amplify and propagate, but not so much as to generate unrestrained autoimmune
tumor immunity, enabling it to amplify and propagate, but not so much as to generate unrestrained
inflammatory responses.
autoimmune inflammatory responses.
We and others have previously shown that local IL-12 gene therapy of malignant melanoma in
We and others have previously shown that local IL-12 gene therapy of malignant melanoma in
patients or in preclinical models has yielded promising results with less toxicity [3]. In this study,
patients or in preclinical models has yielded promising results with less toxicity [3]. In this study, we
we demonstrated that plasmid encoding mouse IL-12 (pIL-12) delivered by GET directly into the
demonstrated that plasmid encoding mouse IL-12 (pIL-12) delivered by GET directly into the tumor
tumor was able to recruit and/or induce the proliferation of immune cells, which led to efficient tumor
was able to recruit and/or induce the proliferation of immune cells, which led to efficient tumor
suppression (Figure 1B–D). Apparently, pIL-12 intratumor injection alone is insufficient to initiate
suppression (Figure 1B–D). Apparently, pIL-12 intratumor injection alone is insufficient to initiate an
an immune response cascade leading to the suppression of tumor growth. We found that through
immune response cascade leading to the suppression of tumor growth. We found that through
manipulation of GET parameters the onset, level, and duration of protein expression of IL-12 can be
manipulation of GET parameters the onset, level, and duration of protein expression of IL-12 can be
controlled, resulting in meaningful therapeutic effects in melanoma without dose-dependent IL-12
controlled, resulting in meaningful therapeutic effects in melanoma without dose-dependent IL-12
toxicities [22].
toxicities [22].
Although IL-12 has been shown to have powerful tumor-suppressing effects in a variety of
Although IL-12 has been shown to have powerful tumor-suppressing effects in a variety of
animal models, the mechanistic underpinning of this phenomenon has never been fully understood,
animal models, the mechanistic underpinning of this phenomenon has never been fully understood,
especially with respect to which immune cells are linked to the mediation of IL-12 induced tumor
especially with respect to which immune cells are linked to the mediation of IL-12 induced tumor
suppression. The data presented in this study shows that beyond the extent of infiltration, the balance
suppression. The data presented in this study shows that beyond the extent of infiltration, the balance
and organization of individual TILs subpopulation are important parameters of B16F10 melanoma
and organization of individual TILs subpopulation are important parameters of B16F10 melanoma
immune microenvironment. B16F10 melanoma immune infiltrate forms a non-continuum (Figure 2)
immune microenvironment. B16F10 melanoma immune infiltrate forms a non-continuum (Figure 2)
where the TILs density decreased progressively from tumor periphery to tumor mass in the no TX
where the TILs density decreased progressively from tumor periphery to tumor mass in the no TX
group, EP1 and EP2. However, the location of TILs moved from the periphery to the tumor mass and
group, EP1 and EP2. However, the location of TILs moved from the periphery to the tumor mass and
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the density of TILs increased after pIL-12 injection only and especially after pIL-12 GET treatment.
We evaluated CD3+ , CD4+ and CD8+ T cell density and frequency. pIL-12 GET resulted in significant
expansion in total number of CD3+ T cells (Figure 2A). Despite the decreased-percentage of PD1
positive cells and Foxp3 positive cells in CD4+ and CD8+ T cells following treatment with EP1 or
EP2 without pIL-12 (Figure 4C–F), tumor growth continued in EP1 and EP2 groups (Figure 1B).
At initial evaluation, this would seem counter to our supposition that conversion from a suppressive
environment to an immune inducing environment and better anti-tumor activity. However, while the
percentages of these cells were reduced, the number of infiltrating CD3+ cells were greatly reduced
compared to pIL-12 GET EP1 or pIL-12 GET EP2 or even pIL-12 injection only (Figures 2–4). The key
to an effective anti-tumor immune response is critically related to the robustness of the lymphocytic
infiltrate as well as the reduction of Treg and PD1+ expression. Overall, our interpretation of this
data is that increases in CD3+ T cells within the TME in tumor-bearing mice do impact tumor growth.
Specifically, in this case, IL12 GET therapy drove an increase in effector T cells. In addition, IL-12
GET therapy resulted in a much lower percentage of Treg and PD1+ cells. Together these factors
resulted in much more pronounced anti-tumor effect. With respect to EP1 and EP2, while there was
a lower percentage of Treg and PD1+ cells, the overall number of CD3 cells were not sufficient to
induce an effective immune response against the tumor. In line with an increase of CD3+ T cells in total
numbers, the frequency of CD8+ T cells was also significantly expanded. In contrast, total CD4+ T cell
frequency decreased compared with the ratio of CD4+ to CD8+ T cells in peripheral blood and spleen,
although there was significantly higher frequency compared with no TX group. When we assessed the
CD4+ Foxp3+ Treg, CD4+ PD1+ and CD8+ PD1+ T cells, the frequency decreased compared with no TX.
Notably, pIL-12 GET recruited abundance of CD4+ T cells, CD8+ T cells and modified their function
within the tumor microenvironment. The results from the TILs revealed a significantly stronger CD8+
T-cell tumor infiltration, a higher CD8+ /CD4+ T-cell ratio, and higher CD8+ PD1− /Treg-cell ratio in
the group of pIL12 GET. High ratios between CD8+ T cells and the other cell types were associated
with improved survival [14,23,24]. In the present study, PD1 expression was down-regulated after
pIL12 GET. These results were in line with other reports [25,26]. Although reports in the literature
regarding the regulation of PD1 expression by IL12 are conflicting, we showed that the percentage of
PD1+ T cells decreased in EP1 and EP2 (Figure 4F) and intratumor pIL12 GET reduced the percentage
of CD8+ PD1+ in CD8+ T cells. Since the number of lymphocytes impact the therapeutic efficacy of
immnunotherapy and pIL12 GET increases lymphocytic infiltrate into the tumor microenvironment
as well as leads to reduction of PD1 expression, it is clear that this approach can play an important
role in enhanced antitumor immunotherapy through the expansion of effector T cells infiltrating into
the tumor. However, the mechanism behind these phenomena still needs further exploration to be
completely delineated.
We propose that peripheral blood monitoring can be used to study responses to pIL-12 GET
induced protection from tumor challenge. Previous studies have shown that IL-12 mediated anti-tumor
immune response was due to T cells and NK cells [4,5,27], so we assessed T and NK cell phenotypes in
peripheral blood. Proliferation of memory (CD44+ ) CD4+ and CD8+ T cells are the major component
for cellular immunotherapy, therefore we also evaluated if there were differences in CD4+ and CD8+ T
memory phenotype across the experimental timeframe. Here, we showed that pIL-12 GET is a strong
immunostimulatory therapy which generally induced CD4+ and CD8+ T cells expansion for cancer.
In addition, treatment with pIL-12 GET can induce a potent proliferation of memory (CD44+ ) CD4+
and CD8+ T cells, but not NK cells in the peripheral blood (Figures 5 and 6) leading to induction of
protection from tumor relapse and metastasis. The results also indicated that the immune response
induced a down-regulation of suppressor cells in mice rechallenged with B16F10 cells after pIL-12
GET (Figure 7). To confirm these results, future experiments will explore depletion of specific immune
subsets, such as CD4+ , CD8+ T cells, NK and Gr-1+ cells.
There are multiple studies that have provided evidence that breaking the stronghold of MDSCs in
the tumor microenvironment is a key step toward effective antitumor immunity. IL-12 and IFN-γ have
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the capacity to convert MDSCs into functional, nonsuppressive antigen-presenting cells [19,27,28].
Our previous studies have shown that treatment with pIL-12 GET therapies for cancer, results in
preferential induction of IFN-γ production [9]. IL-12 led to higher expression of IFN-γ within the
tumor microenvironment, which has been linked to tumor control. Consistent with these previous
studies, we showed that pIL-12 GET treatment decreased in vivo MDSC infiltration of tumors and
increased CD8+ T cell infiltration and survival. The mechanism by which pIL-12 GET alters the
tumor microenvironment revealed that IL-12 initiated infiltration of immune cells into tumor mass,
which in turn changes the tumor microenvironment from a suppressive condition to an antitumor
milieu. Given that PDL1 expression in B16F10 cells (Figure S2) and PD1 expression in CD8+ T cells
(Figures S3 and S4) and that IL-12 activates a local immune response in the primary melanoma via
the recruitment of T lymphocytes to the tumor site as well as triggering the exposure and recognition
of tumor antigens, it may be possible to enhance the antitumor effect by combining pIL-12 GET with
checkpoint inhibitors. This possibility is now being explored, with plans to combine IL-12-mediated
local tumor suppression with blockade of co-inhibitory molecules against PD1 on T cells or PDL1 on
B16F10 melanoma tumor cells.
Although the reasons for the limited clinical efficacy of IL-12 in cancer patients is not fully
understood [8,15,28], several immunosuppressive mechanisms, including CD4+ Treg cell accumulation
due to increased IL-10 production and diminished IFN-γ production after repetitive treatments with
IL-12, could be involved [17,29,30]. In addition, immune suppressive microenvironment characterized
by infiltration of MDSCs in advanced tumors [16,31] could also contribute to the limited efficacy
(Figure S3). To improve the therapeutic efficacy with IL-12 but simultaneously minimize the toxicity,
the next plan will include targeting of pIL-12 to only tumor, and co-administration with a plasmid
encoding anti-CD25 plasmid in order to deplete Treg cells or a plasmid encoding anti-Ly6G to deplete
MDSCs. Thus, IL-12 has a high potential to be used successfully for cancer immunotherapy.
4. Materials and Methods
4.1. Cell Lines, Mice and Tumor Formation
B16F10 murine melanoma cells (ATCC) were maintained in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% FCS and 0.2% gentamicin. All mouse studies were performed
with the approval of the Old Dominion University Institutional Animal Care and Use Committee.
Six-eight-week-old female C57BL/6J mice were obtained from Charles River Laboratories (Wilmington,
MA, USA) and maintained in a specific pathogen-free condition in the host laboratory. The left flank
of female C57BL/6J mice was shaved and 1 × 106 cells in 50 µL of sterile 0.9% saline were injected
subcutaneously. Tumors were measured using digital calipers, and treatment was begun when tumors
reached 50–70 mm3 in volume. Treatment was performed on Days 0, 4 and 7. Intratumoral injection
of plasmid mouse IL-12 (pIL-12, 50 µg/50 µL) with EP1 (six 1300 V/cm, 100 µs pulses with an array
of 6 penetrating electrodes (circular 1 cm diameter array), pIL-12 EP1) or EP2 (ten 600 V/cm, 5 ms
pulses with a non-penetrating caliper electrodes, pIL-12 EP2). Tumor volume was calculated using the
formula v = 0.52 × length × width2 . For rechallenge, mice were injected with 5 × 105 B16F10 cells in
the right flank.
4.2. Plasmid DNA
pUCMV3-mIL-12 (pIL-12, Aldevron, Fargo, ND, USA), containing the murine p35 and p40 IL-12
cDNAs under the control of the cytomegalovirus promoter, was prepared by the manufacturer [3].
4.3. Flow Cytometry for Membrane Staining
EDTA anticoagulant whole blood was used with conjugated antibodies as previously described [12].
After addition of conjugated antibodies, Optilyse B Lysing Solution (Beckman Coulter, Pasadena, CA,
USA) was used to lyse blood cells. Single spleen cells were mixed with antibodies according the
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protocols, after enterocytes lysing with ASK (A1049201, ThermoFisher Scientific, Waltham, MA, USA).
TILs were isolated from tumor tissues by Ficoll-Paque density gradient. Stained-TILs were evaluated
using flow cytometry MACSquant analyzer 10 (Miltenyi, Bergisch Gladbach, Germany).
The following mAbs were used: PE vio770-conjugated anti-CD3 (REA 641), vioblue-conjugated
anti-CD4 (REA 604), APC-vio770-conjugated anti-CD8a (53-6.7), APC-conjugated anti-CD25 (REA 568),
FITC-conjugated anti-CD127 (A7R34), PE-conjugated anti-PD1 (REA 802), PE-conjugated anti-NK1.1
(PK136), APC-conjugated anti-CD11b (REA 596), vioblue-conjugated anti-Gr-1 (RB6-8C5), PerCP
vio 700-conjugated anti-CD45 (REA737), FITC-conjugated anti-CD44 (REA 664), APC-conjugated
anti-CD62L (REA 828). The above antibodies were purchased from Miltenyi (Miltenyi, Bergisch
Gladbach, Germany). FITC-conjugated anti–NKp46 (29A1.4) was purchased from Bio Legend
(San Diego, CA, USA), and analyzed using MACSquant analyzer 10. Additional analysis was
performed using FlowJo software V10 (Tree Star, Inc., Ashland, OR, USA).
4.4. Immunohistochemistry
Fixed-tumor tissues were excised from tumor-bearing mice and fixed using IHC Zinc Fixative
(BD Bioscience, San Jose, CA, USA). Five micrometer paraffin-embedded sections were prepared
for Immunohistochemical staining with Tyramide Signal Amplification (Opal Multiplex IHC Assay,
PerkinElmer, Waltham, MA, USA) to examine the percentage of TILs. The following primary antibodies
were used: rat anti-mouse CD3 (CD3-12), rabbit anti-mouse CD4 (EPR19514), rat anti-mouse CD8a
(4SM15), rat anti-mouse Foxp3 (FJK-16S), rabbit anti-mouse PD1 (EPR20665). The number of immune
cells per section was recorded blind to genotype and normalized to core area. Individual core counts
from 10 or more replicates were available for most cases, and immune cell counts per square millimeter
were averaged across replicates. Cut-off values of low versus high immune cells were defined by the
midpoint. Slides were examined with an Olympus BX51 microscope using Camera Software for DP80
(Olympus America Inc., Center Valley, PA, USA). The cell count of TILs was determined using ImageJ.
The density of TILs calculation as follows:
density o f TIL =
image f ield o f

cells count number
size o f image f ield o f view (mm2 )

view (height, width, diagonal )

=

CCD sensor size (height, width, diagonal)
objective magnification x adapter magnification

4.5. Granzyme B ELISPOT
B16F10 tumor-bearing mice were euthanized and spleens removed. Effector cells from splenocytes
or the positive activation control ConA at 5 mg/mL (Sigma-Aldrich, St Louis, MO, USA) were incubated
with B16F10 target cells for 48 h in 96-well plates in triplicate [12]. Granzyme B enzyme-linked immune
spot (ELISPOT) assays were performed according to manufacturer’s protocol using a commercial
Mouse Granzyme B ELISPOT kit (R&D system, Minneapolis, MN, USA). The plates were scanned and
analyzed on an ImmunoSpot ELISPOT Reader (Cellular Technology Limited, Clevland, OH, USA).
4.6. Cell-Killing Assay with Flow Cytometry
For the killing assay [12], B16F10 tumor cells were labeled with 1 µM carboxyfluorescein succinimidyl
ester (CFSE, Biolegend, San Diego, CA, USA) and used as targets. Effecter cells from spleen were cultured
in round-bottom polystyrene tubes with CFSE labeled target B16F10 cells. After 4 h of incubation of
target and effector cells, propidium iodide (PI) (1 µg/mL, Sigma–Aldrich) was added. The cytotoxic
activity was measured by flow cytometry analysis comparing CFSE+ PI+ cells (killed targets) with
CFSE+ PI− cells (vital targets). Approximately 5000 target cells were acquired.
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4.7. Statistical Analysis
Data were expressed as the mean ± standard error of the mean (SEM). For differences between
groups, one-way ANOVA was used for three or more groups, and student’s t-test was used for two
groups. Survival data from the animal studies were analyzed using the log-rank test. Statistical
analyses were performed with commercially available software (SPSS 16.0 and GraphPad Prism 5,
San Diego, CA, USA).
5. Conclusions
In summary, we show that pIL-12 GET alters the tumor microenvironment from suppressive
condition to antitumor milieu. These data highlight that subsets of CD44+ T memory cells in circulation
are representative of cells at immune sites and underscore the importance of evaluating peripheral
blood when making determinations about immune surveillance being able to successfully prevent
tumor relapse and metastasis. More broadly speaking, these findings may guide the development
of combination cancer therapies to make tumors more accessible for targeted immune therapy and
vaccination to establish long-term antitumor immunity in patients.
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